Light-Activated Protein Conjugation and 89 Zr-Radiolabelling with Water-Soluble Desferrioxamine Derivatives.
Amaury GuillouDaniel F EarleyJason P HollandPublished in: Chemistry (Weinheim an der Bergstrasse, Germany) (2020)
Protein-conjugates are vital tools in biomedical research, drug discovery and imaging science. For example, functionalised monoclonal antibodies (mAbs) coupled to the desferrioxamine B (DFO) chelate and radiolabelled with 89 Zr4+ ions are used as radiopharmaceuticals for diagnostic positron emission tomography (PET). In this context, protein functionalisation requires the formation of a covalent bond that must be achieved without compromising the biological properties of the mAb. Photochemistry offers new synthetic routes toward protein conjugates like 89 Zr-mAbs but to harness the potential of light-induced conjugation reactions new photoactivatable reagents are required. Herein, we introduce two photoactivatable DFO-derivatives functionalised with an aryl azide (ArN3 ) for use in light-activated conjugation and radiosynthesis of 89 Zr-mAbs. Incorporation of a tris-polyethylene glycol (PEG)3 linker between DFO and the ArN3 group furnished water-soluble chelates that were used in the one-pot, photoradiosynthesis of different 89 Zr-radiolabelled protein conjugates with radiochemical yields up to 72.9±1.9 %. Notably, the DFO-PEG3 chelates can be readily synthesised in accordance with Good Laboratory Practice (GLP), which will facilitate clinical trials with photoradiolabelled 89 Zr-mAbs.
Keyphrases
- pet imaging
- water soluble
- positron emission tomography
- computed tomography
- protein protein
- clinical trial
- drug discovery
- binding protein
- healthcare
- cancer therapy
- pet ct
- drug delivery
- high resolution
- small molecule
- randomized controlled trial
- risk assessment
- mass spectrometry
- quantum dots
- quality improvement
- monoclonal antibody
- double blind